The significance of autoantibody changes over time in primary biliary cirrhosis

American Journal of Clinical Pathology

Volumn 144, Issue 4, 2015, Pages 601-606

  Tana, Michele M ^a,b   Shums, Zakera ^b   Milo, Jay ^b   Norman, Gary L ^b   Leung, Patrick S ^c   Gershwin, M Eric ^c   Noureddin, Mazen ^a   Kleiner, David E ^a   Zhao, Xiongce ^a   Heller, Theo ^a   Hoofnagle, Jay H ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b INOVA DIAGNOSTICS INC   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Autoantibodies; Autoimmune liver disease; Primary biliary cirrhosis; Prognosis; Serum markers; Ursodiol

Indexed keywords

AUTOANTIBODY; COPPER; MITOCHONDRION ANTIBODY; AUTOANTIGEN; BIOLOGICAL MARKER; CELL NUCLEUS ANTIGEN; SP100 PROTEIN, HUMAN;

ADULT; ADVERSE OUTCOME; AGED; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DECOMPENSATED LIVER CIRRHOSIS; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER FIBROSIS; LIVER TRANSPLANTATION; MALE; OUTCOME ASSESSMENT; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; PROGNOSIS; THROMBOCYTE COUNT; BILIARY CIRRHOSIS; BLOOD; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROSIS; IMMUNOLOGY; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; ANTIGENS, NUCLEAR; AUTOANTIBODIES; AUTOANTIGENS; BIOMARKERS; COHORT STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROSIS; HUMANS; LIVER CIRRHOSIS, BILIARY; MALE; MIDDLE AGED; PROGNOSIS;

EID: 84947742138     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPQV4A7QAEEFEV     Document Type: Article

References (31)

1. Walker JG, Doniach D, Roitt IM, et al. Serological tests in diagnosis of primary biliary cirrhosis. Lancet. 1965;1:827-831.
2. Lleo A, Invernizzi P, Mackay IR, et al. Etiopathogenesis of primary biliary cirrhosis. World J Gastroenterol. 2008;14:3328-3337.
3. Van de Water J, Cooper A, Surh CD, et al. Detection of autoantibodies to recombinant mitochondrial proteins in patients with primary biliary cirrhosis. N Engl J Med. 1989;320:1377-1380.
4. Muratori P, Muratori L, Ferrari R, et al. Characterization and clinical impact of antinuclear antibodies in primary biliary cirrhosis. Am J Gastroenterol. 2003;98:431-437.
5. Heseltine L, Turner IB, Fussey SP, et al. Primary biliary cirrhosis: quantitation of autoantibodies to purified mitochondrial enzymes and correlation with disease progression. Gastroenterology. 1990;99:1786-1792.
6. Van Norstrand MD, Malinchoc M, Lindor KD, et al. Quantitative measurement of autoantibodies to recombinant mitochondrial antigens in patients with primary biliary cirrhosis: relationship of levels of autoantibodies to disease progression. Hepatology. 1997;25:6-11.
7. Joshi S, Cauch-Dudek K, Heathcote EJ, et al. Antimitochondrial antibody profiles: are they valid prognostic indicators in primary biliary cirrhosis? Am J Gastroenterol. 2002;97:999-1002.
8. Rigopoulou EI, Davies ET, Bogdanos DP, et al. Antimitochondrial antibodies of immunoglobulin G3 subclass are associated with a more severe disease course in primary biliary cirrhosis. Liver Int. 2007;27:1226-1231.
9. Benson GD, Kikuchi K, Miyakawa H, et al. Serial analysis of antimitochondrial antibody in patients with primary biliary cirrhosis. Clin Dev Immunol. 2004;11:129-133.
10. Yang WH, Yu JH, Nakajima A, et al. Do antinuclear antibodies in primary biliary cirrhosis patients identify increased risk for liver failure? Clin Gastroenterol Hepatol. 2004;2:1116-1122.
11. Rigopoulou EI, Davies ET, Pares A, et al. Prevalence and clinical significance of isotype specific antinuclear antibodies in primary biliary cirrhosis. Gut. 2005;54:528-532.
12. Itoh S, Ichida T, Yoshida T, et al. Autoantibodies against a 210 kDa glycoprotein of the nuclear pore complex as a prognostic marker in patients with primary biliary cirrhosis. J Gastroenterol Hepatol. 1998;13:257-265.
13. Muratori P, Muratori L, Cassani F, et al. Anti-multiple nuclear dots (anti-MND) and anti-SP100 antibodies in hepatic and rheumatological disorders. Clin Exp Immunol. 2002;127:172-175.
14. Nakamura M, Shimizu-Yoshida Y, Takii Y, et al. Antibody titer to gp210-C terminal peptide as a clinical parameter for monitoring primary biliary cirrhosis. J Hepatol. 2005;42:386-392.
15. Sfakianaki O, Koulentaki M, Tzardi M, et al. Peri-nuclear antibodies correlate with survival in Greek primary biliary cirrhosis patients. World J Gastroenterol. 2010;16:4938-4943.
16. Wesierska-Gadek J, Penner E, Battezzati PM, et al. Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis. Hepatology. 2006;43:1135-1144.
17. Corpechot C, Abenavoli L, Rabahi N, et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology. 2008;48:871-877.
18. Bressler B, Pinto R, El-Ashry D, et al. Which patients with primary biliary cirrhosis or primary sclerosing cholangitis should undergo endoscopic screening for oesophageal varices detection? Gut. 2005;54:407-410.
19. Lleo A, Selmi C, Invernizzi P, et al. Apotopes and the biliary specificity of primary biliary cirrhosis. Hepatology. 2009;49:871-879.
20. Hu SL, Zhao FR, Hu Q, et al. Meta-analysis assessment of GP210 and SP100 for the diagnosis of primary biliary cirrhosis. PLoS One. 2014;9:e101916.
21. Tang YM, Bao WM, You LY, et al. Clinical features of patients with primary biliary cirrhosis and anti-SP100 autoantibody positivity [in Chinese]. Zhonghua Gan Zang Bing Za Zhi. 2013;21:359-362.
22. Mytilinaiou MG, Meyer W, Scheper T, et al. Diagnostic and clinical utility of antibodies against the nuclear body promyelocytic leukaemia and Sp100 antigens in patients with primary biliary cirrhosis. Clin Chim Acta. 2012;413:1211-1216.
23. Gatselis NK, Zachou K, Norman GL, et al. Clinical significance of the fluctuation of primary biliary cirrhosis-related autoantibodies during the course of the disease. Autoimmunity. 2013;46:471-479.
24. Kisand KE, Metsküla K, Kisand KV, et al. The follow-up of asymptomatic persons with antibodies to pyruvate dehydrogenase in adult population samples. J Gastroenterol. 2001;36:248-254.
25. Metcalf JV, Mitchison HC, Palmer JM, et al. Natural history of early primary biliary cirrhosis. Lancet. 1996;348:1399-1402.
26. Aurangzeb S, Tariq M, Irshad M, et al. Relationship between anti-acetylcholine receptor antibody titres and severity of myasthenia gravis. J Pak Med Assoc. 2009;59:289-292.
27. Sanders DB, Burns TM, Cutter GR, et al. Does change in AChR antibody level correlate with clinical change in MG? Muscle Nerve. 2014;49:483-486.
28. Sievers K. The rheumatoid factor in definite rheumatoid arthritis: an analysis of 1279 adult patients, with a follow-up study. Acta Rheumatol Scand Suppl. 1965:(suppl 9):1-121.
29. Goronzy JJ, Matteson EL, Fulbright JW, et al. Prognostic markers of radiographic progression in early rheumatoid arthritis. Arthritis Rheum. 2004;50:43-54.
30. Rothfield NF, Stollar BD. The relation of immunoglobulin class, pattern of anti-nuclear antibody, and complement-fixing antibodies to DNA in sera from patients with systemic lupus erythematosus. J Clin Invest. 1967;46:1785-1794.
31. Gladman DD, Urowitz MB, Keystone EC. Serologically active clinically quiescent systemic lupus erythematosus: a discordance between clinical and serologic features. Am J Med. 1979;66:210-215.